Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:APRI

Apricus Biosciences (APRI) Stock Price, News & Analysis

Apricus Biosciences logo

About Apricus Biosciences Stock (NASDAQ:APRI)

Key Stats

Today's Range
$0.32
$0.50
50-Day Range
N/A
52-Week Range
$0.18
$3.34
Volume
22,139 shs
Average Volume
558,386 shs
Market Capitalization
$11.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system disorders. The firm's portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior in Major Depressive Disorder �or Post-Traumatic Stress Disorder, �amyotrophic lateral sclerosis, Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases. The company was founded by Raj Mehra in 2016 and is headquartered in New York, NY.

Receive APRI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Apricus Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APRI Stock News Headlines

Is the Trump/Musk duo good for shares of TSLA?
If you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.
See More Headlines

APRI Stock Analysis - Frequently Asked Questions

Apricus Biosciences, Inc. (NASDAQ:APRI) released its quarterly earnings results on Wednesday, October, 31st. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02.

Based on aggregate information from My MarketBeat watchlists, some other companies that Apricus Biosciences investors own include Scotts Miracle-Gro (SMG), Pfizer (PFE), Just Eat Takeaway.com (GRUB), Boston Beer (SAM), Amicus Therapeutics (FOLD), Palatin Technologies (PTN) and Synergy Pharmaceuticals (SGYP).

Company Calendar

Last Earnings
10/31/2018
Today
12/03/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:APRI
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$320,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.76 million
Book Value
$0.29 per share

Miscellaneous

Free Float
N/A
Market Cap
$14.09 million
Optionable
Not Optionable
Beta
1.20
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:APRI) was last updated on 12/3/2024 by MarketBeat.com Staff
From Our Partners